Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Leqembi“
Suchtreffer
Begriffe & Kennungen
Leqembi
Eintrag öffnenLeqembi · 4.1 Therapeutic indications · 1
Eintrag öffnenLeqembi · 4.3 Contraindications · 1
Eintrag öffnenLeqembi · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenLeqembi · 4.3 · Patients with bleeding disorders that are not under adequate control.
Eintrag öffnenLeqembi · 4.3 · Pre-treatment MRI findings of prior intracerebral haemorrhage, more than 4 microhaemorrhages, superficial side
Eintrag öffnenLeqembi · 4.3 · Treatment with lecanemab should not be initiated in patients receiving ongoing anticoagulant therapy (see sect
Eintrag öffnenLeqembi · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenLeqembi · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenLeqembi · 4.5 · Elimination of lecanemab is likely to occur through normal degradation pathways for immunoglobulins and the cl
Eintrag öffnenLeqembi · 4.5 · No drug interaction studies have been conducted with lecanemab.
Eintrag öffnenLeqembi · 4.5 · The risk of intracerebral haemorrhage with lecanemab treatment may be increased in patients receiving anticoag
Eintrag öffnenLeqembi · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenLeqembi · 4.8 Undesirable effects · 1
Eintrag öffnenLeqembi · 4.8 · 10 treatment with or without dose interruption, respectively. Among those that continued, 36% (28/78) of patie
Eintrag öffnenLeqembi · 4.8 · 8 In the double-blind, placebo-controlled period of Study 301 in patients with mild cognitive impairment due t
Eintrag öffnenLeqembi · 4.8 · 9 3 Occurred 24 hours after infusion. 4 ARIA: Includes radiographic ARIA-E, symptomatic ARIA-E, radiographic A
Eintrag öffnenLeqembi · 4.8 · ARIA-H (with or without concurrent ARIA-E) was observed in 13% (98/757) of patients on lecanemab and 7% (52/76
Eintrag öffnenLeqembi · 4.8 · ARIA-H was observed in 13% (98/757) of patients on lecanemab compared with 7% (52/764) of patients on placebo.
Eintrag öffnenLeqembi · 4.8 · ApoE ε4 Carrier Status and Risk of ARIA Approximately 15% of Alzheimer’s disease patients are ApoE ε4 homozygo
Eintrag öffnen